National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Urinary tract infections are common bacterial infections that affect the urethra, bladder, ureter or the kidney. It is the second most common infectious presentation in community medical practice with a high rate of morbidity and financial cost. This infection has burden rate of 150 million cases are estimated per annum while around 8 million cases are attributed to UTI in the USA. The study was conducted in the department of Microbiology, GMCH, Udaipur (Rajasthan), India during the period of year 2014-2015 on 356 patients, clinically diagnosed as Community acquired UTI. 100 non-duplicate urinary isolates of Escherichia coli from patients with clinically evident UTI were included in the study. Samples were collected from the patients after obtaining an informed verbal consent. Method employed for collection of urine was Midstream clean catch technique. Institutional Ethical clearance was obtained before commencement of the study. All relevant laboratory records of every subject was systemically recorded in pre designed data sheet. In this study, age group of 46-55 years was predominantly affected, irrespective of gender. Out of 100 screened strains of Escherichia coli, 33 were found to be ESBL and 67 to be non EBBL producers. The most resistant drug in Urinary Pathogenic Escherichia coli (UPEC) isolates was Ciprofloxacin with resistance rate of 82%. No resistance was observed for Fosomysin. Nitrofurantoin was found to be most susceptible drug with sensitivity rate of 98%. Fosomysin and Nitrofurantoin was found to retain 100% sensitivity, against non ESBL producers. Out of 82 Ciprofloxacin-resistant isolates, Nalidixic acid was most resistant drug with 100% resistance rate. Conclusion: Both Fosomysin and Nitrofurantoin can be used as drug of choice for empirical treatment of community acquired UTI. Resistance to Ciprofloxacin should not be considered as marker for resistance to other Fluoroquinolone. Thus Fluoroquinolone should only be prescribed following culture and sensitivity testing but not for empirical therapy.
Citations |
 |
 |
 |
 |
